Synlogic (SYBX)
Former synthetic biology drug developer now seeking strategic alternatives.
Something off on this page? Send us feedback.
Synlogic is a former clinical-stage biotechnology company that developed Synthetic Biotic live biotherapeutics for rare metabolic disorders. After halting its lead phenylketonuria study, it reduced operations to a public shell focused on strategic alternatives.
Synlogic, Inc. is a Delaware biopharmaceutical issuer that previously advanced engineered probiotic-based Synthetic Biotic medicines for rare metabolic disorders, including labafenogene marselecobac for phenylketonuria and SYNB1353 for homocystinuria. In February 2024, the company stopped the Synpheny-3 pivotal trial after an internal review indicated the study was unlikely to meet its main endpoint, while the decision was not tied to safety or tolerability concerns.
Since then Synlogic has sharply reduced its workforce and operating activities, retained a small public-company infrastructure, and focused on evaluating strategic alternatives such as a merger, sale, asset transaction, or other transaction. Nasdaq later viewed Synlogic as a public shell, and the company reported that its common stock moved from Nasdaq quotation to OTC quotation in January 2026, while it remained an SEC-reporting company.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.2M · Total debt $0 · Total assets $13.5M · Shareholders' equity $12.0M
- Revenue
- $0
- Operating income
- −$838.0K
- Net income
- −$543.0K
No dividends on record.
| Institutions2 holders · as of Mar 31, 2026 | 0.19% | 23.8K shares | |
| Insiders5 holders · as of Oct 31, 2025 | 11.48% | 1.41M shares | |
| Otherremainder | 88.33% | 10.82M shares |
12.25M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Baselake Partners, LPInstitution | 9.31% | 1.14M | 13Gfiled Jan 23, 2026 ↗ |
Kryzanowski, John A.Insider | 5.99% | 733,412 | 13Gfiled Feb 25, 2025 ↗ |
Radoff Bradley LouisInsider | 5.14% | 629,211 | 13Gfiled Apr 18, 2024 ↗ |
DRW Securities, LLCInstitution | 0.19% | 23,763 | 13Fas of Mar 31, 2026 |
Richard P. SheaInsiderdirector | 0.13% | 15,506 | Form 4filed Apr 29, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 27, 2026 | New Enterprise Associates 14, L.P. | director, 10 percent owner: | +2,640,845 | $0.7000 |
| Oct 29, 2025 | Mary Beth Dooley | officer: See Remarks below | −157 | $1.81 |
Not reported.